Reply
We thank Drs Brotman and Girod for their interesting comment on our article. They direct our attention to a possible alternative explanation for the proposed role of peripheral fat mass (PFM) as an independent antiatherogenic factor. They propose that the inverse association between PFM and atherosclerosis may reflect endogenous variation in the tone of the HPA axis with resulting high glucocorticoid levels associated with central fat distribution and low glucocorticoid levels associated with peripheral fat distribution. Unfortunately, our study design does not allow meaningful extrapolation from measures of plasma cortisol. However, to validate their hypothesis, we have retrieved measures of bone and muscle mass from all participating women as reliable surrogate variables reflecting long-term HPA-axis activity. To our great surprise, we have found that in all 4 groups, women with central adiposity had the highest bone mineral density (BMD) and the highest amount of muscle mass on the legs. BMD at the lumbar spine (0.950Ϯ0.135 versus 0.864Ϯ0.178 g/cm 2 ; PϽ0.05), distal forearm (0.389Ϯ0.010 versus 0.336Ϯ0.010 g/cm 2 ; PϽ0.001), and hip (0.840Ϯ0.16 versus 0.780Ϯ0.22 g/cm 2 , PϽ0.05) were all significantly higher in women with central compared with peripheral adiposity. Similarly, total leg lean mass was also significantly higher in patients with central adiposity; 13.36Ϯ0.19 versus 11.27Ϯ0.21 kg, respectively (PϽ0.001). After adjustment for body mass index, BMD at the distal forearm and leg lean tissue mass continued to show significant differences. Thus, these results do not seem to provide support for a significant contribution of the HPA axis to the findings of our study. We believe that it is still important to look for other underlying mechanisms to explain the independent antiatherogenic effect of PFM observed in our study. 1 
